Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Pfizer License Agreement	Convertible Preferred Stock	Convertible Preferred Stock Pfizer License Agreement	Initial Public Offering	Common Stock	Common Stock Pfizer License Agreement	Common Stock Initial Public Offering	Additional paid-in capital	Additional paid-in capital Pfizer License Agreement	Additional paid-in capital Initial Public Offering	Accumulated deficit
Beginning balance at Dec. 31, 2020			$ 21,942
Beginning Balance, Shares at Dec. 31, 2020			22,724,925
Beginning balance at Dec. 31, 2020	$ (15,645)					$ 1			$ 97			$ (15,743)
Beginning Balance, Shares at Dec. 31, 2020						1,289,342
Issuance of Series B convertible preferred stock			$ 152,081	$ 20,000
Issuance of Series B convertible preferred stock, Shares			92,660,103	12,152,145
Issuance of common stock					$ 152,296			$ 11			$ 152,285
Issuance of common stock (Shares)								10,500,000
Temporary equity, Conversion of Series A and Series B convertible preferred stock into shares of common stock			$ (194,023)
Temporary equity, Conversion of Series A and Series B convertible preferred stock into shares of common stock (Shares)			(127,537,173)
Conversion of Series A and Series B convertible preferred stock into shares of common stock	194,023					$ 20			194,003
Conversion of Series A and Series B convertible preferred stock into shares of common stock (Shares)						20,056,145
Stock options exercised	170								170
Stock options exercised (Shares)						70,396
Vesting of restricted common stock	3								3
Vesting of restricted common stock (Shares)						306,998
Stock-based compensation	6,441								6,441
Net loss	(75,975)											(75,975)
Ending balance at Dec. 31, 2021	261,313					$ 32			352,999			(91,718)
Ending balance (in shares) at Dec. 31, 2021						32,222,881
Issuance of common stock		$ 4,281					$ 2			$ 4,279
Issuance of common stock (Shares)							2,229,654
Stock options exercised	$ 183								183
Stock options exercised (Shares)	73,841					73,841
Vesting of restricted common stock (Shares)						432,354
Stock-based compensation	$ 15,764								15,764
Net loss	(120,717)											(120,717)
Ending balance at Dec. 31, 2022	$ 160,824					$ 34			$ 373,225			$ (212,435)
Ending balance (in shares) at Dec. 31, 2022						34,958,730